Mice transgenic for the rat HER-2/neu oncogene (rNeu-TG) developed spontaneous breast tumors that can escape a rNeu-specific immune response induced by active specific immunotherapy (ASI). The ability of these escape tumors to grow appeared to be due to upregulation of the Fas ligand (Fas-L) molecule. In an effort to develop tools for the better elucidation of the role of Fas-L and other regulatory mechanisms in tumor escape, we established cell lines derived from escape tumors. These tumor cell lines retained MHC class I, rNeu and Fas-L expression in vitro and formed tumors in vaccinated mice. Tumor growth was accompanied by permanent Fas-L expression in vivo, both in vaccinated and control vaccinated mice, indicating that these cells have acquired constitutive Fas-L expression. Moreover, these cells induced target cell apoptosis in vitro. Thus, these cells represent a unique tool to elucidate the importance of Fas-L expressed by tumors that escaped efficient systemic immune responses. Cell Death and Differentiation (2001) 8, 687 ± 695.
Introduction
The identification of tumor-associated antigens (TAAg) expressed on tumor cells has allowed the development of active specific immunotherapy (ASI) protocols. TAAg-specific immune responses have demonstrated rejection and/or regression of various established tumors in animal models. However, numerous studies have indicated that tumors can develop passive and/or active escape mechanisms to evade the immune system in immunized animals. 1 Loss of TAAg, downregulation of MHC molecules, 2 ± 4 lack of costimulatory molecules 5 ± 7 and upregulation of immune-suppressive factors have been reported. 8 ± 10 Recent reports have identified Fas (CD95, APO-1) ligand (Fas-L) as a molecule participating in tumor resistance to the immune system. Human tumors such as melanoma, 9 hepatoma, 11 gastro-intestinal cancer, 10, 12, 13 lung cancer 14 and breast carcinoma 15 ± 18 have been shown to express Fas-L and to induce apoptosis of T cells in vitro. Apoptosis of tumor infiltrating lymphocytes was found in areas of Fas-L expressing tumor cells. 12 These observations led to the hypothesis of tumor counterattack by which Fas-L expressing cancers might delete tumor-specific lymphocytes and promote evasion from an anti-tumor immune response. 19, 20 In contrast, other reports demonstrated that cells engineered to express high levels of Fas-L did not confer immune privilege but rather induced a proinflammatory granulocytic infiltration that resulted in rapid elimination of the transplanted cells. 21 ± 24 These contradictory results indicated that the role of Fas-L to promote tumor escape in vivo needed to be further validated. In particular, no study so far has conclusively demonstrated that a tumor constitutively expressing Fas-L could delete specific anti-tumor lymphocytes and escape vaccinationinduced immune rejection.
Transgenic mice (rNeu-TG) in which the rat oncogene HER-2/neu (rNeu) is overexpressed in the mammary gland epithelium develop spontaneous breast tumors after a first pregnancy. 25 We have previously shown that a vaccine consisting of allogeneic fibroblasts overexpressing rNeu (Balbc/neu) prevented spontaneous tumor formation while late escape tumors developed in some vaccinated mice. 26 Our data further showed that escape tumors upregulated Fas-L in mice with a persistent rNeu-specific systemic immune response and indicated that Fas-L expression promoted T cell apoptosis in situ and enabled tumor escape. 27 Tumor cell lines represent a widely used tool to investigate the role of Fas-L in tumor escape. Tumor rejection was mainly observed when Fas-L-transfected cells were used and suggested Fas-L (over) expressing cells to be responsible for non-specific immunologic reactions such as the documented granulocytic infiltrations. 21 ± 24 However, cell lines derived from Fas-L-expressing escape tumors may offer more reliable models to assess Fas-L involvement in tumor escape from ASI. We established and characterized here tumor cell lines derived from Fas-L + escape tumors that developed in vaccinated rNeu-TG mice. We showed that these cell lines maintained rNeu, MHC class I and Fas-L expression in vitro, formed tumors in Balbc/neu vaccinated mice and induced Fas-L-dependent target cell apoptosis in vitro. Thus, these cell lines represent a unique tool to investigate the mechanism of Fas-L-dependent tumor escape after ASI in vivo.
Results

Tumor cells derived from escape tumors maintain their ability to grow in vaccinated mice
We investigated whether tumor cells that escaped from an efficient immune response after ASI would maintain their tumor formation capacity after transplantation into vaccinated mice. Cell suspension from one representative escape tumor (mouse #241) was reinjected in vaccinated mice as shown in Figure 1 . Escape tumor cells formed tumors at the injection sites irrespective of whether transplanted in mice vaccinated with control allogeneic fibroblasts (Balbc/mock) or with fibroblasts transfected with rNeu (Balbc/neu). 26 These escape properties were maintained when newly formed tumors (from mouse #490) were passaged into a Balbc/neu vaccinated mouse (mouse #557). In contrast, Balbc/neu vaccinated mice repetitively rejected a challenge with a cell suspension of spontaneous tumor cells derived from an unvaccinated mouse (e.g. mouse #345), although these cells remained tumorigenic in Balbc/mock vaccinated mice. We have previously shown that most escape tumors expressed Fas-L on their cell surface. 27 To investigate whether Fas-L expression was maintained in passaged escape tumors we assessed Fas-L expression by immunohistochemical staining. All but one (#491) tumors that developed from escape tumor #241 expressed significant levels of Fas-L. Identical results were obtained with different transplanted escape tumors (not shown). In contrast, spontaneous tumors transplanted in Balbc/mock vaccinated mice did not upregulate Fas-L expression. These results indicated that escape properties and Fas-L expression were maintained after transplantation of escape tumors in vaccinated mice.
Phenotypic characterization of an escape tumor cell line
To further assess the function of naturally occurring Fas-L on tumor cells that escaped ASI, we generated stable cell lines from spontaneous and escape tumors. Two representative cell lines derived from a spontaneous (NF9006) and as escape tumor (#493) were further analyzed. Both tumor cell lines grew in vitro as a monolayer with an epithelial-like morphology and stained positive for pan-cytokeratin (not shown). As depicted in the FACS histograms in Figure 2A , NF9006 and #493 cells expressed similar levels of rNeu. In contrast, the #493 escape tumor cell line expressed higher levels of MHC class I (H-2D q L q , IgG2a) molecules. Both NF9006 and #493 cell lines were negative for MHC class II (I-A q , IgG2a isotype-matched control) and for CD80 and CD86 (not shown). Fas-L surface expression was assessed using a mAb recognizing the extracellular part of murine Fas-L (IgG2a). The escape tumor cell line #493 expressed elevated levels of Fas-L on the cell surface in comparison to the weak Fas-L levels on NF9006 cells. Previous studies have reported inconsistency in Fas-L detection by flow cytometric analysis depending on the mAb used. 28 To further confirm increased Fas-L protein production in #493 cells, immunohistochemical staining was performed on cytospins using a rabbit polyclonal antibody against the intracellular part of Fas-L ( Figure 2B ). The spontaneous tumor cell line NF9006 showed only a faint staining for Fas-L while significant Fas-L protein level was detected in the cytoplasm and membrane of #493 cells. We also performed RT ± PCR for Fas-L on total RNA extracted from NF9006 and #493 tumor cells. No fragment was amplified from RNA extracts without reverse transcriptase ruling out DNA contamination. The resulting PCR product was the expected size of 547 bp (data not shown) and showed an identical sequence as the reported murine Fas-L. 29 The escape cell line #493 maintains the capacity of tumor formation in Balbc/neu vaccinated mice
We then investigated whether the #493 tumor cell line expressing Fas-L and cultured in vitro maintained its escape capacity in vivo. NF9006 and #493 cells (0, 5 ± 2610 6 ) were injected into Balbc/mock or Balbc/neu-vaccinated mice and time to tumor formation and kinetics of tumor growth were assessed. As shown in Table 1 Figure  3 ). In contrast, nine of 10 mice vaccinated with Balbc/mock exhibited a tumor size of 41.5 cm 2 50 days after challenge, whereas at this time point four Balbc/neu vaccinated mice had tumors 51.5 cm 2 and three mice showed still no tumor at the injection site. At day 50, mice vaccinated with Balbc/mock fibroblasts showed a mean tumor size of 3.12 cm 2 (S.E.M. 0.71), whereas mice vaccinated with Balbc/neu cells had a mean tumor size of 1.53 cm 2 (S.E.M. 0.3). Tumors formed in mice irrespective of whether they were injected with 0.5, 1 or 2610 6 tumor cells. However there was a significant delay of tumor growth/size in Balbc/neu vaccinated mice (Mann ± Whitney rank test P50.024). Moreover, NF9006 formed tumors in all Balbc/mock vaccinated mice and no tumor was observed in Balbc/neu vaccinated mice as described previously. 26 These experiments showed that the #493 cells derived from an escape tumor maintained the tumorigenic and escape capacity of the originating tumor.
Injected #493 cells maintain Fas-L expression in vivo
To test whether Fas-L was still expressed in vivo in the longterm follow up, #493 and NF9006 cells were injected into Balbc/neu and Balbc/mock vaccinated mice and expression of Fas-L in situ was assessed by immunohistochemistry at the injection site. As shown in Figure 4A , #493 cells injected into Balbc/neu vaccinated mice formed disrupted tumor islets by day 5 and most tumor cells stained positive for Fas-L. We have previously shown that escape tumor cells injected in Balbc/neu vaccinated mice were infiltrated by a large number of CD3 + lymphoid cells in the tumor implant as well as the surrounding tissue. 27 We further showed that expression of Fas-L on tumor cells correlated with local induction of T cell apoptosis as predominantly, cells in the close periphery of injected escape tumor cells, stained positive for active caspase-3. The regions of caspase-3 activity overlapped Figure 3 Tumor kinetics of injected escape tumor cell lines in vaccinated mice. Results as in Table 1 
Escape tumor cell lines induce apoptosis of Fas-L-sensitive target cells
We next investigated whether Fas-L expressed on tumor cells might be functionally responsible for the induction of apoptosis of infiltrating T cells. 27 We used the P815 mastocytoma cell line transfected with murine Fas cDNA as Fas-L-sensitive target cells in a modified cytotoxicity test. Figure 5B indicated that cytotoxicity induced by #493 was mainly mediated by Fas-L as the addition of Fas-Fc fusion protein inhibited DNA fragmentation. The same inhibition of DNA fragmentation was observed when #242 escape tumor cells were used as effector cells and Fas-Fc protein was added to the culture system (data not shown). In contrast, Fas-Fc fusion protein had no effect on cell cultures with P815-WT or in coculture systems with NF9006 as effector cells. Thus, the capacity of Fas-L expressing #493 cells to kill Fas-sensitive target cells and its inhibition by Fas-Fc fusion protein strongly suggests a role of constitutively expressed Fas-L on tumor cells as an active tumor escape mechanism.
Discussion
We have previously shown that some rNeu-TG mice developed late escape mammary tumors after a rNeuspecific vaccination with Balbc/neu fibroblasts. 27 These escape tumors expressed elevated levels of surface Fas-L that appeared to promote tumor escape from rNeu specific immune response after vaccination. This created a unique opportunity for the isolation of cell lines that constitutively expressed Fas-L. We showed here that cell lines derived from rNeu + escape tumors maintained the Fas-L expression of the original tumor and were tumorigenic in Balbc/neu vaccinated mice, in contrast to a tumor cell line derived from a spontaneous tumor that developed in unvaccinated mice. Fas-L plays a pivotal role in lymphocyte cytotoxicity and in the maintenance of immunologic homeostasis 32 and has been implicated in immune privilege of various organs, such as the eye and testis by inducing apoptosis of activated T lymphocytes. 33, 34 Immune privilege has also become a new focus in tumor immune evasion, as various types of cancer cells including breast cancer, 15 ± 18 hepatocellular carcinomas, 11 colon cancer 10 and melanoma 9 have been described to express Fas-L. The functional activity of tumor-derived Fas-L was demonstrated in vitro by the induction of apoptosis of activated T cells and in vivo by the detection of apoptotic T cells in the vicinity of Fas-L expressing tumors. 9 ± 14 We have shown in our rNeu-TG mouse model a predominant expression of Fas-L on escape tumor cells. We further demonstrated here that Fas-L also expressed on a representative escape tumor cell line that formed tumors in vaccinated mice. Moreover, we previously described apoptotic T cells in close proximity of Fas-L expressing escape tumors, in contrast to Fas-L negative spontaneous tumors. 27 However, the initial observations of Fas-L expression on melanoma cells and the induction of apoptosis of activated T cells 9 were not confirmed by subsequent studies, 21, 35 putting Fas-L in question as a tumor counterattack mechanism. 20, 36 Fas-L detection on some tumor samples has suffered from technical inconsistencies based on unspecific Abs, 28, 37 and the lack of Fas-L detection using FACS or RT ± PCR. 21, 35, 38 We demonstrated Fas-L expression on escape tumor cell lines by FACS analysis, thus avoiding lymphocyte contamination that may contribute to Fas-L detection in fresh tumor samples, by immunohistochemistry using a different antibody both on cytospins and on tumor samples after reinjection in vivo and by RT ± PCR using specific primers and sequencing of the resulting fragment.
Further controversies arose when transplanted cells, engineered to express Fas-L either by transgene expression, 22, 23 by transfection 24 or by transduction with an adenoviral vector, 21 were shown to exhibit a proinflammatory effect that resulted in a profound infiltration of neutrophils and in tumor rejection. This immunologic reaction was explained by the apoptotic death of T cells and other Fas-expressing cells and the production of IL-1b through their activated cascade of caspase proteases or of IL-8 by endothelial cells. 39 These observations significantly differ from our results, as we failed to detect an inflammatory infiltration of neutrophils in growing escape tumors or after injection of escape tumor cells. This is consistent with our previous observation that tumor rejection was mediated by T cells 26 and that apoptotic T cells were specifically found in close proximity of Fas-L + escape tumor cells. 27 Moreover, we demonstrated here that Table 1 and Figure 3 ), indicating that these cells were not simply outnumbering the immune response, but displayed an active immunosuppressive mechanism in situ to escape the systemic rNeu-specific immune response. The significant delay of escape tumor progression in Balbc/neu vaccinated mice in comparison to Balbc/mock vaccinated mice may result from the different degree of Fas-L expression on escape tumors. The faint Fas-L expression in IHC and FACS analysis of the spontaneous tumor cell line (NF9006) indicated that a Fas-L expression above a certain threshold was necessary for tumor cells to escape an ASI.
Tumor escape from immune response appears a complex mechanism that, besides Fas-L, likely involves other immunomodulatory factors, such as TGF-b. 40 The availability of escape tumor cell lines constitutively expressing both a clinically relevant TAAg (rNeu) and Fas-L may help to clarify some of the controversies surrounding the involvement of Fas-L in tumor escape mechanisms. 20, 36 In particular, protocols to prevent Fas-L expression or Fas-L-mediated escape in vivo could be investigated. This may be of relevance in future clinical trials of ASI in patients with breast cancer, as Fas-L expression was shown in various breast carcinomas and derived cell lines.
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Materials and Methods
Mice MMTV/r-Neu FVB mice (H-2 q ) transgenic for the rat neu protein (rNeu-TG) were purchased from Charles River, Germany. Animal care was in accordance to institutional guidelines. Transgenic animals were identified by PCR for rNeu as described previously. 26 
Cell lines
Balb/c 3T3 (H-2 d ) fibroblasts transfected with a SV2-Neo-SP65 plasmid alone (Balbc/mock) or together with the pBR322-rNeu plasmid (Balbc/neu) have been described previously. 26 
Establishment of spontaneous and escape tumor-derived cell lines
Tumors were excised and minced into small pieces (50.5 mm each) in PBS and incubated for 20 min at 378C in the presence of Trypsin/ EDTA (Sigma, Buchs, Switzerland). The cell suspension was filtered through a 0.45 mm cell strainer (Becton Dickinson, Heidelberg, Germany), washed in DMEM supplemented with 10% FCS, and grown in William's E medium supplemented with 10% FCS, antibiotics (penicillin/streptomycin), 2 mM glutamin, and 10 75 M b-mercaptoethanol (all from Sigma). Established cell lines were then progressively adapted from William's E (Sigma) to DMEM medium. The rNeu + breast cancer cell line NF9006 was cloned from a spontaneous breast adenocarcinoma as described. 41 
Vaccination protocols
For vaccination/challenge experiments, mice were vaccinated and boosted (after 14 days) intraperitoneally (i.p.) with 5610 6 Balbc/neu or Balbc/mock fibroblasts. Two weeks after the boost, mice were challenged by subcutaneous (s.c.) injection of 0.5 ± 2610 6 rNeu + spontaneous or escape tumor cells. Tumor formation and size was assessed every 3 ± 4 days using a calibrator. Tissues were collected for histological and immunohistochemical analysis at indicated time points.
Immunohistochemistry
Paraffin-embedded tissues were deparaffinized and pretreated by microwave heating in 10 mM citrate buffer, pH 6.0. Slides were incubated with either a rabbit anti-HER-2/neu (Dako, Copenhagen, Denmark), a rabbit anti-Fas-L (N-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a rabbit anti-topoisomerase IIa (TOPOIIAp, Novocastra Laboratories, Newcastle, UK) polyclonal antibody (Ab) diluted in TCGA buffer (Tris 50 mM, pH 7.5 supplemented with 1% casein, 0.02% NaN 3 and 5% normal goat serum). Alternatively, cytospins were incubated with a mouse anti-pan-cytokeratin (Sigma), a rabbit anti-Fas-L (N20) or rabbit anti-Fas (Oncogene Research, MA, USA) polyclonal Ab diluted in TCGA. After incubation with biotin-conjugated goat anti-mouse or goat anti-rabbit Ab (Dako), reactivities were detected using alkaline phosphatase-conjugated avidin-biotin complex (Dako) and Newfuchsin substrate (Sigma) according to manufacturer's instructions. Stainings were scored as described. 27 
FACS analysis
Cells were incubated at 48C for 30 min with mouse anti-rNeu Ab-4 (Oncogene Science, Tarzana, CA, USA) or biotinilated anti-Fas-L (H11, IgG2a from Alexis, Lausen, Switzerland), anti-H-2D q /L q , anti-I-A q , anti-CD80 or anti-CD86 mAbs (IgG2a, all from Pharmingen, San Diego, CA, USA), washed with PBS, followed by incubation with FITC-conjugated Streptavidin or FITC-conjugated goat anti-mouse IgG (Southern Biotechnology, Birmingham, AL, USA) and analyzed for fluorescence on a FACScan (Becton Dickinson, Heidelberg, Germany).
RT ± PCR for Fas-L
Total RNA was extracted from 5610 6 tumor cells using the SVTotal RNA Isolation system (Promega, Madison, WI, USA) according to manufacturer's instructions. One mg RNA was subjected to reverse transcriptase reaction (RT) using 0.5 mg oligo p(dT) 15 primer, 0.4 mM dNTP nucleotide mix (Roche Diagnostics, Rotkreuz, Switzerland) and the M-MLV reverse transcriptase (Promega) for 1 h at 428C. Total RNA extracts without reverse transcriptase was used as control ruling out DNA contamination. RT reaction was stopped by incubation at 958C for 5 min. cDNA was then subjected to 40 PCR cycles (1 min at 958C, 1 min at 628C, 1.5 min at 728C) using intron-spanning primers: 5-CACTGACCCCTCTAAAGAAGAA-3' (forward) and 5'-TTGAATACTGCCCCCAGGTA-3' (reverse). Presence of a 547-bp fragment was analyzed on an agarose gel. Fas-L fragment was further confirmed by sequencing (Microsynth GmbH, Balgach, Switzerland).
Co-culture DNA fragmentation assay (JAM test)
Target Fas-transfected P815-4.2 (P815-Fas) and P815 wild type (P815-WT) cells were kindly provided by K Matsuura and P Vassalli, (Geneva, Switzerland). The cell death was quantitated by measuring
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Fas-L function on escape tumor cells D Ce Â fai et al target cell DNA fragmentation using the JAM test with some modifications. 30, 31 In brief, breast cancer cell lines (NF9006 and #493) were seeded in flat bottom 96-well plates and incubated overnight. Thereafter, 5000 P815-WT or P815-Fas target cells were added that had been labeled by prior incubation with 2.5 mCi/ml of [ 3 H]thymidine at 378C for 18 ± 22 h. After a coculture of 6 ± 8 h cells were removed from the wells by adding 5 mM EDTA and collected onto a glass fiber filter. The radioactivity of intact chromosomal DNA retained on filters was measured by liquid scintillation counting. Specific killing was calculated using the following equation: % Specific killing (S À E/S) Â 100 where E (experimental) is c.p.m. of retained DNA in the presence of effector cells, and S (spontaneous) is c.p.m. of retained DNA in target cells in the absence of effector cells. Soluble Fas-L was obtained from supernatant of Neuro-2a cells stabily transfected with Fas-L as described previously 42 and kindly provided by A Fontana (Zurich, Switzerland). Where indicated Fas-Fc fusion protein was added to the cultures to inhibit Fas/Fas-L activity at a concentration of 20 mg/ml according to manufacturer's instructions (Alexis).
